How Long Can You Stay on Menopausal Hormone Therapy?

Evidence reconciled August 29, 2026. The article has not yet received a new clinician review; medical/expert approval is required before publication.

The duration question is really five questions

“How many years?” sounds precise, but it hides the variables that actually change the answer. This continuation map makes those variables visible.

The useful output is not “approved for another year.” It is a short record of the current indication, the regimen, the material risks, alternatives, and what would prompt an earlier review.

What current guidance actually says

The Menopause Society's 2022 position statement says treatment should be individualized and periodically reevaluated. For people younger than 60 or within 10 years of menopause onset without contraindications, it describes the benefit-risk ratio as favorable for bothersome vasomotor symptoms and prevention of bone loss. It also says longer duration should be tied to documented indications such as persistent symptoms, with shared decision-making [1].

The advisory panel states the continuation threshold directly: “Longer durations of therapy should be for documented indications such as persistent VMS, with shared decision-making and periodic reevaluation” [1]. Here, VMS means vasomotor symptoms such as hot flashes and night sweats. This consensus language supports a review process; it is not an endorsement of HealthRX.com, a particular regimen, or indefinite treatment.

ACOG's patient guidance reaches the same practical endpoint: discuss every year whether to continue, based on current symptoms, risks, and benefits [2]. “Every year” is a review cadence, not a one-year prescription limit.

FDA labeling also changed materially in 2026. The agency approved removal of cardiovascular disease, breast cancer, and probable dementia statements from the boxed warning on six MHT products. The FDA did not erase those risks from clinical decision-making: relevant warnings remain elsewhere in systemic-product labels, and systemic estrogen alone retains a boxed warning about endometrial cancer [3]. A label change is therefore not evidence that every regimen is risk-free or suitable indefinitely.

Starting later and continuing longer are not interchangeable

The strongest recurring error in duration advice is treating these as the same scenario.

• Starting systemic MHT near menopause: for a healthy symptomatic person younger than 60 or within 10 years of menopause onset, the average benefit-risk balance is usually more favorable [1].
• Starting for the first time later: absolute risks of coronary heart disease, stroke, venous thromboembolism, and dementia are higher with older age and later initiation, so the case for starting needs more scrutiny [1].
• Continuing after 60 or 65: age alone does not create a mandatory stop. Persistent symptoms or another documented indication can support continuation after a fresh review of regimen and risk.

This distinction prevents two opposite mistakes: forcing a stable patient to stop because of a birthday, and telling a new older patient that years since menopause do not matter.

The WHI does not supply one expiration date

The Women's Health Initiative (WHI) randomized two specific regimens: conjugated equine estrogen (CEE) alone in participants with a prior hysterectomy, and CEE plus medroxyprogesterone acetate (MPA) in participants with a uterus. Median treatment was 7.2 and 5.6 years, respectively. These trials were not head-to-head tests of every current patch, gel, estradiol dose, or progestogen.

After more than 20 years of cumulative follow-up, randomized CEE alone was associated with lower breast-cancer incidence and mortality than placebo, while CEE plus MPA was associated with higher breast-cancer incidence [4]. That divergence is the lesson: “hormone therapy” is not one exposure. The findings cannot prove that estrogen alone prevents breast cancer in ordinary practice, nor can the combined arm quantify every estradiol-plus-micronized-progesterone regimen.

The WHI also does not support prescribing systemic MHT to prevent chronic disease. A 2024 review of the randomized program concluded that the trials do not support MHT for primary prevention of cardiovascular disease or other chronic diseases [5]. Symptom treatment and primary prevention are different decisions.

What deserves attention at a continuation review

The symptom or indication

Record what improves on treatment and what returns during a supervised dose change. Hot flashes can last far longer than the old “couple of years” story; see the hot-flash duration guide for the cohort evidence. Bone protection may be relevant, but fracture prevention requires its own risk assessment and alternatives rather than a generic “HRT is good for bones” conclusion.

The route and components

Oral and transdermal estrogen do not have identical pharmacology. A person using a patch has a different discussion from someone using oral estrogen, although “transdermal” does not mean risk-free. The estradiol patch dosing guide explains the formulation rather than converting routes milligram-for-milligram.

If the uterus is present, the clinician must also confirm that the progestogen plan adequately protects the endometrium. Nighttime drowsiness from oral micronized progesterone may be noticeable, but it is not proof that the endometrial regimen is adequate; see the oral micronized progesterone menopause guide.

Changes that should not wait for the annual visit

New unexplained vaginal bleeding after menopause needs assessment. So do a new clot, stroke, heart attack, breast-cancer diagnosis, major liver disease, or a new severe neurologic symptom. Do not stop or restart prescription hormones on the basis of an internet checklist; contact the prescribing clinician promptly so the event and the regimen can be evaluated together.

Stopping is a trial, not a moral achievement

There is no reliable test that predicts whether vasomotor symptoms will recur after stopping. Some people taper, while others stop at once; evidence has not established one universal method that prevents recurrence. A planned trial can define what is being tested, how symptoms will be recorded, and what threshold would justify resuming or choosing a nonhormonal option.

Do not improvise by stretching doses or alternating products. If a dose is unintentionally missed, use the product-specific instructions and the HealthRX.com missed-dose overview.

The decision in one sentence

Continue systemic MHT while there is a documented benefit that still matters, the current regimen's risks remain acceptable to the individual, endometrial protection is adequate when needed, and the decision is periodically revisited. Duration alone cannot answer any of those questions.